Clinical Trials
임상시험 트래커
국내사는 전체 임상 이력, 글로벌 메이저는 진행 중 파이프라인을 추적합니다. ClinicalTrials.gov API v2에서 6시간 주기로 수집합니다.
기업
60 results (top 60)
- 2상모집 예정· Chronic Lymphocytic LeukemiaTP53 변이가 있는 만성 림프구성 백혈병 환자에서 Epcoritamab과 Venetoclax 및 Ibrutinib 병용
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
협력: 애브비
- 2상모집 예정· Refractory Diffuse Large B-Cell Lymphoma (DLBCL)2차 CAR T세포 치료 후 재발·불응성 대B세포림프종에 대한 에프코리탐맙·레날리도마이드 병용요법
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
협력: 애브비
- 2상모집 예정· EoE반응하지 않는 호산구성 식도염에 대한 우파다시티닙 임상시험
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
협력: 애브비
- 2상모집 중· Chronic Lymphocytic Leukemia만성 림프구백혈병 및 소림프구림프종 치료를 위한 베네톨락스와 자누브루티닙 병용
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
협력: 애브비
- 2상모집 예정· Head and Neck Squamous Cell Carcinoma재발성 또는 전이성 두경부 편평세포암종의 일차 치료를 위한 텔리소투주맙 아디주테칸과 펨브롤리주맙의 안전성 및 용량 평가 연구
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
리드: 애브비
- 2상모집 예정· Pancreatobiliary Cancers담췌암 성인 참가자에서 텔리소투주맙 아디주테칸 병용 치료의 부작용 및 질병 활성도 변화 평가 연구
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
리드: 애브비
- 2상모집 중· Obesity비만 또는 과체중 및 체중 관련 동반질환을 가진 성인에서의 ABBV-295의 안전성 및 유효성
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
리드: 애브비
- 2상모집 중· Crohn's Disease중등도에서 중증의 활성 크론병 또는 궤양성 대장염이 있는 성인 참여자의 치료를 위한 고급 치료법 연구
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
리드: 애브비
- 2상모집 중· Forehead Lines성인의 중등도에서 중증 이마 주름 치료를 위한 AGN-151586 주사의 안전성 및 효능 평가 연구
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants
리드: 애브비
- 2상모집 중· Upper Limb Essential Tremor상지 본태성 진전을 가진 성인 환자에서 AGN-151607-DP의 이상 반응 및 질병 활동 변화 평가 연구
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
리드: 애브비
- 2상모집 중· Chronic Lymphocytic Leukemia (CLL)재발 만성림프구성백혈병 환자에서 아칼라부루티닙+베네토클락스 유한 기간 치료의 제2상 연구
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
리드: 아스트라제네카 · 협력: 애브비, 로슈
- 2상모집 중· Lung Non-Small Cell CarcinomaTelisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
협력: 애브비
- 2상모집 중· Idiopathic Pulmonary FibrosisStudy of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
리드: 애브비
- 2상모집 중· Major Depressive DisorderA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
리드: 애브비
- 2상모집 중· Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
협력: 애브비
- 2상모집 중· Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
협력: 애브비
- 2상모집 중· Small Cell Lung CancerA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
리드: 애브비
- 2상모집 중· Epithelial Ovarian CancerA Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
리드: 애브비
- 2상모집 중· Waldenstrom MacroglobulinemiaA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
협력: 애브비, 일라이 릴리
- 2상모집 중· Aggressive Diffuse Large B-cell LymphomaCombining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
협력: 애브비
- 2상모집 중· Marginal Zone LymphomaEpcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
협력: 애브비
- 2상모집 중· Bipolar I or II DisorderStudy to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
리드: 애브비
- 2상모집 중· Primary CNS Lymphoma (PCNSL)Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
협력: 애브비
- 2상모집 중· Intensive Chemotherapy UnfitAlternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
협력: 애브비
- 2상모집 중· Rheumatoid ArthritisA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
리드: 애브비
- 2상모집 중· Advanced High-Grade Epithelial Ovarian CancerA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
리드: 애브비
- 2상모집 중· Generalized Anxiety Disorder (GAD)Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
리드: 애브비
- 2상모집 중· Psoriatic ArthritisStudy of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
리드: 애브비
- 2상모집 중· Waldenstrom MacroglobulinemiaEfficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
협력: 애브비, 화이자
- 2상모집 중단 (진행 중)· Mantle Cell LymphomaGATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
협력: 애브비, 일라이 릴리, 로슈
- 2상모집 중· T-cell Acute Lymphoblastic LeukemiaAdding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
협력: 애브비
- 2상모집 중단 (진행 중)· Locally Advanced Unresectable or Metastatic Gastric AdenocarcinomaA Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
리드: 애브비
- 2상모집 중· Relapsed or Refractory Acute Myeloid Leukemia (AML)BCL2i CLAG-M in R/R Acute Myeloid Leukemia
협력: 애브비
- 2상모집 중· Acute Myeloid LeukemiaDiscontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
협력: 애브비
- 2상모집 중· Gram-negative Bacterial InfectionA Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
리드: 화이자 · 협력: 애브비
- 2상모집 중· Relapsed/Refractory Large B-cell LymphomaMRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
협력: 애브비
- 2상모집 중· Acute Myeloid LeukemiaVenetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
협력: 애브비
- 2상모집 중단 (진행 중)· Unresectable Metastatic Colorectal CancerStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
리드: 애브비
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.